These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7974334)

  • 1. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group.
    Alhenc-Gelas M; Jestin-Le Guernic C; Vitoux JF; Kher A; Aiach M; Fiessinger JN
    Thromb Haemost; 1994 Jun; 71(6):698-702. PubMed ID: 7974334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study.
    Meyer G; Brenot F; Pacouret G; Simonneau G; Gillet Juvin K; Charbonnier B; Sors H
    Thromb Haemost; 1995 Dec; 74(6):1432-5. PubMed ID: 8772215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).
    Bratt G; Aberg W; Johansson M; Törnebohm E; Granqvist S; Lockner D
    Thromb Haemost; 1990 Dec; 64(4):506-10. PubMed ID: 1964751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.
    Bratt G; Törnebohm E; Granqvist S; Aberg W; Lockner D
    Thromb Haemost; 1985 Dec; 54(4):813-7. PubMed ID: 3911482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
    Monreal M; Lafoz E; Olive A; del Rio L; Vedia C
    Thromb Haemost; 1994 Jan; 71(1):7-11. PubMed ID: 8165649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
    Mismetti P; Reynaud J; Tardy-Ponce B; Laporte-Simitsidis S; Scully M; Goodwyn C; Queneau P; Decousus H
    Thromb Haemost; 1995 Aug; 74(2):660-6. PubMed ID: 8585003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight heparin for treatment of acute myocardial infarction (FAMI): Fragmin (dalteparin sodium) in acute myocardial infarction.
    Kakkar VV; Iyengar SS; De Lorenzo F; Hargreaves JR; Kadziola ZA;
    Indian Heart J; 2000; 52(5):533-9. PubMed ID: 11256775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis -- results of the European multicenter ADVENT trial.
    Bounameaux H; Ehringer H; Hulting J; Rasche H; Rapold HJ; Zultak M
    Thromb Haemost; 1997 Sep; 78(3):997-1002. PubMed ID: 9308743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J; Johnston N; Siegbahn A
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
    DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.
    Lindmarker P; Holmström M; Granqvist S; Johnsson H; Lockner D
    Thromb Haemost; 1994 Aug; 72(2):186-90. PubMed ID: 7831649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
    Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
    Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
    Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A
    Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.
    Bechtold H; Gunzenhauser D; Sawitzki H; Fung S; Janssen D
    Z Kardiol; 2003 Jul; 92(7):532-9. PubMed ID: 12883837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of postoperative deep vein thrombosis in cancer patients. A randomized trial with low molecular weight heparin (CY 216).
    Marassi A; Balzano G; Mari G; D'Angelo SV; Della Valle P; Di Carlo V; D'Angelo A
    Int Surg; 1993; 78(2):166-70. PubMed ID: 8394842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Secondary prevention after deep venous thrombosis. Low molecular weight heparin versus coumarin].
    Hamann H
    Zentralbl Chir; 1999; 124(1):24-6. PubMed ID: 10091293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 3,000 IU aXa of the low molecular weight heparin certoparin with 5,000 IU aXa in prevention of deep vein thrombosis after total hip replacement. German Thrombosis Study Group.
    Adolf J; Fritsche HM; Haas S; Hennig FF; Horbach T; Kastl S; Koppenhagen K; Michaelis HC; Rhamanzadeh R; Summa W; Wagner W; Weber U; Wolf H
    Int Angiol; 1999 Jun; 18(2):122-6. PubMed ID: 10424367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Home treatment of deep vein thrombosis: a two-years experience of a single institution.
    Grau E; Real E; Pastor E; Viciano V; Aguiló J
    Haematologica; 1998 May; 83(5):438-41. PubMed ID: 9658729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.